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JPET #54197; page 5 About 30% of epileptic patients do not respond to the usual antiepileptic drugs (AEDs) representing a major health problem associated with increased morbidity and mortality (Regesta and Tanganelli, 1999 ). An important characteristic of pharmacoresistant epilepsy is that these patients do not respond to most, and often all AEDs pointing to nonspecific and possibly adaptive mechanisms. The underlying cause is not completely understood; mechanisms leading to AED resistance are most likely complex network phenomena and may include development of tolerance to AED action or alterations in drug targets (including genetic factors). A currently favored hypothesis is the overexpression of multidrug transporters especially P-glycoprotein (Pgp) in the blood-brain barrier (BBB) (Abbott et al., 2002; Löscher and Potschka, 2002) restricting the access of these drugs to their site of action.
Pgp (gene product of the multidrug resistance 1 (MDR1) gene) contributes to renal, biliary and intestinal elimination of drugs and is expressed at the BBB (Kusuhara et al., 1998; van Asperen et al., 1997; van Asperen et al., 1998; Schinkel et al., 1994) . At the BBB Pgp is localized in the apical membrane of brain capillary endothelial cells (BCECs) where it transports substrates towards the blood compartment (van Asperen et al., 1997; Cordon-Cardo et al., 1989) . Therefore, this transporter can limit the penetration into and retention within the brain and thus modulate effectiveness and central nervous system (CNS) toxicity of numerous compounds (Schinkel et al., 1996; Schinkel et al., 1994) . The brain expression of Pgp is markedly increased in the majority of patients with intractable partial epilepsy (Tishler et al., 1995) suggesting that at least in some resistant patients the overexpression of drug transporters might contribute to AED refractoriness. This assumption was further supported by other studies demonstrating an overexpression of multidrug transporters in BCECs and brain tissue from treatment resistant patients (Dombrowski et al., JPET #54197; page 6 phenytoin, carbamazepine, and valproate are substrate of the multidrug resistance-associated protein (MRP) (Potschka et al., 2001; Potschka and Löscher, 2001b; Huai-Yun et al., 1998) .
Furthermore, recent evidence suggests a possible role of the C3435T polymorphism of the MDR1 gene in pharmacoresistant epilepsy (Siddiqui et al., 2003) .
Interestingly, in certain cases pharmacoresistance can be overcome by add-on therapy with a second AED (Jette et al., 2002; Marson et al., 2000; Ramaratnam et al., 2001 ) raising the question of whether the co-administered drug acts by inhibition of Pgp. We therefore investigated the Pgp inhibitor potency of the most prevalent AEDs using the well-established in vitro calcein assay and confocal laser-scanning microscopy with bodipy-verapamil as Pgp substrate.
JPET #54197; page 8 under standard cell culture conditions with medium M199 supplemented with 10% heat inactivated fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate. To maintain Pgp expression, the culture medium for L-MDR1 was supplemented with 0.64 µM vincristine. For the calcein assay, cells were seeded on collagencoated microtiter plates in a density of 10.000 cells/cm 2 and cultured for three days. For confocal laser-scanning microscopy, about 1x10 6 cells were seeded onto poly-D-lysine and collagen coated coverslips (diameter 30 mm) and cultured for four days. One day before the assays, both cell lines were fed with vincristine-free culture medium.
Porcine Brain Capillary Endothelial Cells (pBCECs)
As a model for the BBB we used pBCECs. The isolation of these cells was essentially based on the method described by Audus and co-workers (Audus et al., 1996) with minor changes and after thorough validation as described previously (Weiss et al., 2003) . Cells were seeded on collagen-coated microtiter plates in a density of 100.000 cells/cm 2 and cultured under standard cell culture conditions with medium M199 containing L-glutamine (0.7 mM), streptomycin sulfate (100 µg/ml), penicillin G (100 U/ml), HEPES (10 mM), and 10% heatinactivated horse serum. Eight days after seeding the confluent monolayers were used for the calcein assay.
Stock Solutions
Stock solutions of test compounds were prepared strictly following the manufacturers instructions. Gabapentin, sodium valproate, topiramate, and vigabatrin were soluble in aqua bidest. Carbamazepine, lamotrigine, sodium phenobarbital, sodium phenytoin, quinidine, verapamil hydrochloride, and LY335979 were dissolved in DMSO. The DMSO concentration in the assays never exceeded 1% (v/v), a concentration that was found not to influence the results of the assay in pilot experiments.
This article has not been copyedited and formatted. The final version may differ from this version. Triton X-100 for 15 min. Calcein fluorescence generated within the cells was analyzed in a Fluoroskan Ascent fluorometer (Labsystems, Frankfurt, Germany) with 485 nm excitation and 535 nm emission filters. Each experiment was performed at least in duplicate (if no effect was observed) or in triplicate on different days.
Confocal Laser-Scanning Microscopy
Intracellular accumulation of the Pgp substrate bodipy-verapamil (Lelong et al., 1991) Only areas with confluent cell monolayers were used for quantification. The experiment was performed at least in triplicate on different days and the values were averaged. LLC-PK1 cells were used as a control.
Quenching Test
Each test compound was analyzed for possible quenching effects on calcein fluorescence. To simulate the conditions of the calcein assay, we generated calcein by incubating LLC-PK1 cells with 1 µM calcein-AM for 60 min at 37 °C on a rotary shaker at 450 rpm. Increasing concentrations of the test compounds were added to aliquots of the cell lysate and the fluorescence was compared to control wells without test compounds.
All compounds were also tested for quenching effects on bodipy-verapamil fluorescence. To exclude possible self-quenching effects of calcein and bodipy-verapamil, we ascertained that the fluorescence of these dyes was linear up to the respective concentration applied in the assays.
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Results

Method Validation
Expression of Pgp in the cell lines used and exclusion of possible involvement of MRP1 and MRP2, which may also transport calcein-AM, were demonstrated as described previously (Weiss et al., 2003) . The suitability of the confocal laser-scanning microscopy for detecting
Pgp inhibition in L-MDR cells was demonstrated with the well-known Pgp inhibitor LY335979, which showed a significant increase in basal bodipy-verapamil fluorescence already at a concentration of 1 nM ( None of the test compounds was cytotoxic in any of the cell lines even at the highest concentrations used.
Evaluation of the Pgp Inhibitory Potency of AEDs
Of all AEDs tested, only carbamazepine significantly increased the intracellular calcein concentration in pBCECs at concentrations >10 µM and in L-MDR1 cells at concentrations >200 µM, but not in the control cell line LLC-PK1 ( Using confocal laser-scanning microscopy, carbamazepine-induced inhibition was confirmed (Table 1 , Fig. 2 ) and phenytoin, lamotrigine, and valproate also inhibited Pgp (Table 1, Fig. 3). Carbamazepine, lamotrigine, phenytoin, and valproate in concentrations >100 µM significantly increased the uptake of bodipy-verapamil. Carbamazepine and phenytoin even doubled the basal fluorescence at 500 µM (Table 1 ). There was no siginificant effect of 500 µM carbamazepine, lamotrigine, phenytoin, and valproate on bodipy-verapamil accumulation in LLC-PK1 cells. All other AEDs had no significant effect either in L-MDR1 or in LLC-PK1 cells (Table 1 , Fig. 3 ).
This article has not been copyedited and formatted. The final version may differ from this version. . These studies thus raise the question of whether their superiority might be caused by changes in drug distribution to the site of action.
Pgp is an efflux transporter that may confer drug resistance in cancer chemotherapy and anti-HIV therapy. Indirect evidence suggests that this might also be a cause for impaired drug responses in epilepsy (Tishler et al., 1995; Dombrowski et al., 2001; Sisodiya et al., 2002) .
Moreover, Pgp activity may substantially affect the kinetics of many drugs and may contribute to numerous pharmacokinetic drug-drug interactions (Yu, 1999) . Thus far the impact of Pgp on bioavailability, distribution, and excretion of AEDs and its role in the interaction with co-administered drugs (including AEDs in combination therapy) has not been thoroughly investigated.
While for some AEDs like carbamazepine, lamotrigine, phenobarbital, and phenytoin Pgp- Effective concentrations in the in vitro assays were clearly higher than therapeutic plasma concentrations present after usual therapeutic doses (lying between 20 and 100 µM for all studied compounds except valproate (300-600 µM)). Even when considering the fact that carbamazepine, phenytoin, and lamotrigine may accumulate in the human brain by factor 1.2-2.8 (Meyer et al., 1999; Sironi et al., 1980) , it seems unlikely that the weak inhibition found for these AEDs is of clinical relevance in the monotherapy with AEDs. However, our study does not exclude, that inhibition might be potentiated in add-on therapies, when two AEDs 
